Endo Dives Deeper Into Devices With AMS Acquisition

With its $2.9 billion acquisition of American Medical Systems, Endo Pharmaceutical Holdings is further diversifying its specialty pharma portfolio into devices and services.

With its $2.9 billion acquisition of American Medical Systems Holdings Inc., Endo International PLC is further diversifying its specialty pharma portfolio into devices and services. The two companies announced an agreement April 11 in which Endo will acquire the urology device specialist for $30 per share, a move that furthers Endo's strategy to become a leader in the area of pelvic health services and products. [See Deal] The healthy offer represents a 34% premium over AMS' April 8 closing price – and is three times the device maker's 2010 sales of $538 million. The combined company is estimated to have sales of $2.68 billion.

Endo – once inordinately dependent on Lidoderm (lidocaine 5% patch) for revenues – has been in the midst of a...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Business Strategy

Late-Stage GLP-1 Drug Trials Outside The Cardiometabolic Space

 
• By 

A look at Novo Nordisk, Eli Lilly and other companies' late-stage clinical studies of GLP-1 drugs in indications ranging from neurodegeneration to oncology, and alcoholic liver disease to autoimmune conditions.

Rising Leaders 2025: Metsera’s Whit Bernard’s Musical Path To Biotech Leadership

 
• By 

Metsera CEO Whit Bernard applies an unconventional leadership philosophy to develop next-generation obesity therapeutics, including monthly GLP-1 injections and oral peptides.

AI In Drug Discovery: The Patent Implications

 
• By 

A Q&A with DeAnn Smith, partner and co-chair of the Patent Trial and Appeal Board Proceedings Practice Group at law firm Foley Hoag.

Is Advanced AI Revolutionizing Sales Enablement In Pharma?

 
• By 

Advanced AI is revolutionizing sales enablement by addressing training gaps and performance challenges. Used correctly, it can help to bridge the sales-marketing divide, accelerate ramp-up times and provide managers with data-driven insights.

More from In Vivo

Pharma’s Dance With Trump Risks Distracting From Longer-Term Threats

 
• By 

Industry is trying to side-step President Trump’s tariff- and price-curbing policy proposals. It may do better facing up to enduring R&D productivity and drug affordability challenges.

Tackling Fraud In The UK: Pharma, Are You Ready?

 
• By 

UK pharma faces a critical turning point as the Economic Crime and Corporate Transparency Act introduces the "Failure to Prevent Fraud" offense in September 2025, requiring companies to transform their approach to fraud prevention or face severe consequences.

Rising Leaders 2025: Kura Oncology’s Mollie Leoni On Setting Precedent, Not Following It

 
• By 

Kura Oncology's new chief medical officer discusses her path to leadership, the company's advancing AML pipeline, and her methodical approach to developing treatments for underserved oncology indications.